Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Prev Alzheimers Dis. 2022;9(1):113–118. doi: 10.14283/jpad.2021.49

Table 1.

Characteristics of Eligible Studies

Table 1 Race/Ethnicity Reported (n=26) Race/Ethnicity Not Reported (n=16)
Sample size, median (range) 289 (56 – 48835) 68 (18 – 6377)
Weighted Mean Age, median yr, (range) 73 (52 – 82) 70 (58 – 88)
% Females, median (range) 69 (22 – 100) 64 (55 – 78)
Females, median n (Range) 230 (34 – 48835) 41 (10 – 72)
% Race/Ethnicity median (range)
American Indian or Alaska Native 0.4 (0.2 – 0.4) --
Asian 2.0 (0.6 – 11.9) --
Biracial -- --
Black or African American 10.8 (1.1 – 94.5) --
Hispanic Ethnicity (any race) 9.6 (0.9 – 100) --
Hawaii Native or Pacific Islander 0.1 (0.1 – 0.1) --
Other or Unspecified 4.9 (0.7 – 42.9) --
White, non-Hispanic 84.8 (57.1 – 97.2) --
Race/Ethnicity
median n (range)
American Indian or Alaska Native 16 (5 – 203) --
Asian 47 (16 – 1107) --
Biracial -- --
Black or African American 77 (2 – 5266) --
Hispanic Ethnicity (any race) 53 (2 – 1854) --
Hawaii Native or Pacific Islander 3 (3 –3) --
Other or Unspecified 26 (3 – 646) --
White, non-Hispanic 197 (55 – 39759) --
Intervention Language, n
English 24 16
Spanish 1 0
English and Spanish 1 0
Funding
Industry 2 0
Intramural 1 0
Mixed 4 7
National Institutes of Health 17 3
Private 3 1
Unknown 0 5

Some combination of race and/or ethnicity was reported in 26 studies. Number or percentage of individuals who were white were reported in 23 trials, Black or African American in 15 trials, Asian in 6 trials, American Indian or Alaska Native in 3 trials, Hawaii Native or Pacific Islander in 1 trial. Hispanic ethnicity was reported in 10 trials and appeared to be included as a separate ethno-racial category with no overlap with race. Funding identification based on sources listed in text.